Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2017 Feb 18

PMID 28209529

Citations 11

Authors

Kyle Staller

Mary K Townsend

Hamed Khalili

Raaj Mehta

Francine Grodstein

William E Whitehead

Catherine A Matthews

Braden Kuo

Andrew T Chan

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Low estrogen levels can contribute to development of fecal incontinence (FI) in women after menopause by altering neuromuscular continence mechanisms. However, studies have produced conflicting results on the association between menopausal hormone therapy (MHT) and risk of FI.

Methods: We studied the association between MHT and risk of FI among 55,828 postmenopausal women (mean age, 73 years) who participated in the Nurses' Health Study, were enrolled since 2008, and with no report of FI. We defined incident FI as a report of at least 1 liquid or solid FI episode per month during 4 years of follow-up from self-administered, biennial questionnaires administered in 2010 and 2012. We used Cox proportional hazard models to calculate multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) for FI risk in women receiving MHT, adjusting for potential confounding factors.

Results: During more than 185,000 person-years of follow-up, there were 6834 cases of incident FI. Compared with women who never used MHT, the multivariate hazard ratio for FI was 1.26 (95% CI, 1.18-1.34) for past users of MHT and 1.32 (95% CI, 1.20-1.45) for current users. The risk of FI increased with longer duration of MHT use (P trend ≤ .0001) and decreased with time since discontinuation. There was an increased risk of FI among women receiving MHT that contained a combination of estrogen and progestin (hazard ratio, 1.37; 95% CI, 1.10-1.70) compared with estrogen monotherapy.

Conclusions: Current or past use of MHT was associated with a modestly increased risk of FI among postmenopausal women in the Nurses' Health Study. These results support a potential role for exogenous estrogens in the impairment of the fecal continence mechanism.

Citing Articles

Clinical application of double-capsule fecal catheter device in ICU patients with fecal incontinence.

Xu Q, Liu Y, Lin J, Zhang H, Wang F, Li Z Am J Transl Res. 2023; 15(9):5882-5890.

PMID: 37854203 PMC: 10579000.

Effects of testosterone treatment on anal sphincter damage repair in ovariectomized rats.

Senyuva I, Acar D, Demirel H, Tunc E Turk J Med Sci. 2023; 53(2):475-485.

PMID: 37476872 PMC: 10388087. DOI: 10.55730/1300-0144.5607.

Emerging approaches to polypharmacy among older adults.

Mehta R, Kochar B, Kennelty K, Ernst M, Chan A Nat Aging. 2023; 1(4):347-356.

PMID: 37117591 DOI: 10.1038/s43587-021-00045-3.

Faecal incontinence in adults.

Bharucha A, Knowles C, Mack I, Malcolm A, Oblizajek N, Rao S Nat Rev Dis Primers. 2022; 8(1):53.

PMID: 35948559 DOI: 10.1038/s41572-022-00381-7.

Proinflammatory Diet Is Associated With Increased Risk of Fecal Incontinence Among Older Women: Prospective Results From the Nurses' Health Study.

Yang K, Tabung F, Whitehead W, Giovannucci E, Chan A, Staller K Clin Gastroenterol Hepatol. 2022; 21(6):1657-1659.e3.

PMID: 35504561 PMC: 9617809. DOI: 10.1016/j.cgh.2022.04.011.

References

Copas P, Bukovsky A, Asbury B, Elder R, Caudle M . Estrogen, progesterone, and androgen receptor expression in levator ani muscle and fascia. J Womens Health Gend Based Med. 2001; 10(8):785-95. DOI: 10.1089/15246090152636541. View

Nojkov B, Rubenstein J, Chey W, Hoogerwerf W . The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol. 2010; 105(4):842-7. PMC: 2887235. DOI: 10.1038/ajg.2010.48. View

Baik C, Strauss G, Speizer F, Feskanich D . Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 2010; 19(10):2525-33. PMC: 2952036. DOI: 10.1158/1055-9965.EPI-10-0450. View

Oettling G, Franz H . Mapping of androgen, estrogen and progesterone receptors in the anal continence organ. Eur J Obstet Gynecol Reprod Biol. 1998; 77(2):211-6. DOI: 10.1016/s0301-2115(97)00212-1. View

Townsend M, Matthews C, Whitehead W, Grodstein F . Risk factors for fecal incontinence in older women. Am J Gastroenterol. 2012; 108(1):113-9. PMC: 3537864. DOI: 10.1038/ajg.2012.364. View

Hendrix S, Cochrane B, Nygaard I, Handa V, Barnabei V, Iglesia C . Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005; 293(8):935-48. DOI: 10.1001/jama.293.8.935. View

Ng K, Sivakumaran Y, Nassar N, Gladman M . Fecal Incontinence: Community Prevalence and Associated Factors--A Systematic Review. Dis Colon Rectum. 2015; 58(12):1194-209. DOI: 10.1097/DCR.0000000000000514. View

Matthews C, Whitehead W, Townsend M, Grodstein F . Risk factors for urinary, fecal, or dual incontinence in the Nurses' Health Study. Obstet Gynecol. 2013; 122(3):539-45. PMC: 3952631. DOI: 10.1097/AOG.0b013e31829efbff. View

Townsend M, Curhan G, Resnick N, Grodstein F . Postmenopausal hormone therapy and incident urinary incontinence in middle-aged women. Am J Obstet Gynecol. 2008; 200(1):86.e1-5. PMC: 2637519. DOI: 10.1016/j.ajog.2008.08.009. View

10.

Haadem K, Ling L, Ferno M, Graffner H . Estrogen receptors in the external anal sphincter. Am J Obstet Gynecol. 1991; 164(2):609-10. DOI: 10.1016/s0002-9378(11)80032-3. View

11.

Bharucha A, Dunivan G, Goode P, Lukacz E, Markland A, Matthews C . Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Am J Gastroenterol. 2014; 110(1):127-36. PMC: 4418464. DOI: 10.1038/ajg.2014.396. View

12.

Bharucha A, Zinsmeister A, Locke G, Seide B, McKeon K, Schleck C . Risk factors for fecal incontinence: a population-based study in women. Am J Gastroenterol. 2006; 101(6):1305-12. DOI: 10.1111/j.1572-0241.2006.00553.x. View

13.

Grodstein F, Manson J, Stampfer M, Rexrode K . Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med. 2008; 168(8):861-6. PMC: 4001717. DOI: 10.1001/archinte.168.8.861. View

14.

Rao S, Bharucha A, Chiarioni G, Felt-Bersma R, Knowles C, Malcolm A . Functional Anorectal Disorders. Gastroenterology. 2016; . PMC: 5035713. DOI: 10.1053/j.gastro.2016.02.009. View

15.

Manson J, Hsia J, Johnson K, Rossouw J, Assaf A, Lasser N . Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349(6):523-34. DOI: 10.1056/NEJMoa030808. View

16.

Sarna L, Bialous S, Jun H, Wewers M, Cooley M, Feskanich D . Smoking trends in the Nurses' Health Study (1976-2003). Nurs Res. 2008; 57(6):374-82. PMC: 6706268. DOI: 10.1097/NNR.0b013e31818bf38b. View

17.

Pinedo G, Garcia E, Zarate A, Leon F, Bellolio F, Molina M . Are topical oestrogens useful in faecal incontinence? Double-blind randomized trial. Colorectal Dis. 2008; 11(4):390-3. DOI: 10.1111/j.1463-1318.2008.01624.x. View

18.

Varma M, Brown J, Creasman J, Thom D, Van Den Eeden S, Beattie M . Fecal incontinence in females older than aged 40 years: who is at risk?. Dis Colon Rectum. 2006; 49(6):841-51. PMC: 1557355. DOI: 10.1007/s10350-006-0535-0. View

19.

Khalili H, Higuchi L, Ananthakrishnan A, Manson J, Feskanich D, Richter J . Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology. 2012; 143(5):1199-1206. PMC: 3480540. DOI: 10.1053/j.gastro.2012.07.096. View

20.

Pares D, Iglesias M, Pera M, Pascual M, Torner A, Baro T . Expression of estrogen and progesterone receptors in the anal canal of women according to age and menopause. Dis Colon Rectum. 2010; 53(12):1687-91. DOI: 10.1007/DCR.0b013e3181f05422. View